AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Airsupra (albuterol/budesonide) by Quarter
Airsupra (albuterol/budesonide) — Worldwide product sales ($M) ($M)
AstraZeneca Airsupra (albuterol/budesonide): $50M in Q2 2026, up 19.0% from a year earlier.
Where the Q2 2026 figure comes from
“|| Airsupra | 50 | | 19 | | 18 | | 45 | | 9 | | 5 | | n/m | | n/m | | - | | - | | - | | - | | - | | -”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Airsupra (albuterol/budesonide) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 50 | +19.0% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 37 | +32.1% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 51 | +104.0% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 45 | +114.3% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 42 | +200.0% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 28 | +300.0% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 25 | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 21 | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 14 | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 7 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
Breakdown
What makes up airsupra (albuterol/budesonide)
Cite this data
StockData. (2026). AstraZeneca Airsupra (albuterol/budesonide) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-airsupra-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.